AR081409A1 - PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV) - Google Patents

PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV)

Info

Publication number
AR081409A1
AR081409A1 ARP110101750A ARP110101750A AR081409A1 AR 081409 A1 AR081409 A1 AR 081409A1 AR P110101750 A ARP110101750 A AR P110101750A AR P110101750 A ARP110101750 A AR P110101750A AR 081409 A1 AR081409 A1 AR 081409A1
Authority
AR
Argentina
Prior art keywords
virus
rabia
parapoxvirus
recombining
dna derived
Prior art date
Application number
ARP110101750A
Other languages
English (en)
Inventor
Olivier Michel Martinon
Nanda Kumar Damavarapu Reddy
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR081409A1 publication Critical patent/AR081409A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Parapoxvirus recombinantes que comprenden ADN heterologo en el genoma, derivado de un virus de la rabia, la preparacion de dichos constructos y su uso en composiciones inmunogénicas y vacunas, También al uso de parapoxvirus recombinantes para diagnostico de animales infectados. Reivindicacinn 17: Un método para inducir una respuesta inmune contra el virus de la rabia en un animal, caracterizado porque comprende administrarle a dicho animal una cantidad inmunologicamente eficaz de una composicion inmunogénica de acuerdo con la reivindicacion 15. Reivindicacinn 18: El método de acuerdo con la reivindicacion 17, caracterizado porque la respuesta inmune es la induccion de anticuerpos de suero de antiproteína G.
ARP110101750A 2010-05-21 2011-05-20 PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV) AR081409A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34698810P 2010-05-21 2010-05-21
US41428710P 2010-11-16 2010-11-16

Publications (1)

Publication Number Publication Date
AR081409A1 true AR081409A1 (es) 2012-08-29

Family

ID=44972661

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101750A AR081409A1 (es) 2010-05-21 2011-05-20 PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV)

Country Status (17)

Country Link
US (1) US20110287051A1 (es)
EP (1) EP2571521A1 (es)
JP (1) JP5890399B2 (es)
KR (2) KR20130008645A (es)
CN (1) CN103260644A (es)
AR (1) AR081409A1 (es)
AU (1) AU2011254315B2 (es)
BR (1) BR112012029633A8 (es)
CA (1) CA2798055C (es)
CL (1) CL2012003219A1 (es)
CO (1) CO6670515A2 (es)
MX (1) MX338052B (es)
NZ (1) NZ603431A (es)
RU (1) RU2545694C2 (es)
UY (1) UY33400A (es)
WO (1) WO2011145013A1 (es)
ZA (1) ZA201208264B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014116334A1 (de) * 2014-11-10 2016-05-12 Eberhard Karls Universität Tübingen Medizinische Fakultät Herstellung von rekombinanten Expressionsvektoren
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
US11013798B2 (en) * 2016-03-21 2021-05-25 South Dakota Board Of Regents Orf virus-based platform for vaccine delivery
CN111944769B (zh) * 2020-08-10 2022-06-28 塔里木大学 一种狂犬病毒g蛋白-羊痘病毒重组疫苗的构建方法
WO2022033573A1 (zh) * 2020-08-13 2022-02-17 苏州般若生物科技有限公司 一种突变型羊传染性脓疱皮炎病毒及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
EP0237686A1 (en) * 1986-03-18 1987-09-23 Institut Pasteur DNA sequences derived from the rabies virus genome
JP2000507092A (ja) * 1996-02-28 2000-06-13 バイエル・アクチエンゲゼルシヤフト 外来ｄｎａを含むパラポックスウイルス、それらの製造及びワクチンにおけるそれらの使用
US6844000B2 (en) * 2001-12-07 2005-01-18 Bayer Pharmaceuticals Corporation Use of Parapox B2L protein to treat cancer and modify immune responses
DK1418942T3 (da) 2001-12-10 2005-11-28 Bavarian Nordic As Poxvirus-holdige sammensætninger og fremgangsmåde til fremstilling deraf
AU2008363648B9 (en) * 2008-10-31 2013-08-22 Tremrx, Inc. Vaccination with poxvirus vectors via mechanical epidermal disruption

Also Published As

Publication number Publication date
US20110287051A1 (en) 2011-11-24
RU2012149036A (ru) 2014-06-27
RU2545694C2 (ru) 2015-04-10
ZA201208264B (en) 2014-01-29
EP2571521A1 (en) 2013-03-27
MX2012013451A (es) 2013-01-22
CO6670515A2 (es) 2013-05-15
CA2798055A1 (en) 2011-11-24
BR112012029633A8 (pt) 2017-12-05
CN103260644A (zh) 2013-08-21
CL2012003219A1 (es) 2013-04-05
CA2798055C (en) 2015-11-24
UY33400A (es) 2011-12-30
AU2011254315B2 (en) 2015-05-14
AU2011254315A1 (en) 2013-01-10
KR20130008645A (ko) 2013-01-22
WO2011145013A1 (en) 2011-11-24
JP5890399B2 (ja) 2016-03-22
NZ603431A (en) 2014-06-27
BR112012029633A2 (pt) 2016-09-20
JP2013535953A (ja) 2013-09-19
KR20150015551A (ko) 2015-02-10
MX338052B (es) 2016-03-31

Similar Documents

Publication Publication Date Title
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
MX347997B (es) Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle.
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
EA201071365A1 (ru) Моноклональные антитела, имеющие гомоподтип кросс-нейтрализующих свойств против вируса гриппа а подтипа н1
PH12015500308B1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
AR081409A1 (es) PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV)
RU2015135890A (ru) Композиция вакцины
AR061894A1 (es) Vacunas para malaria
AR071910A1 (es) Vacuna combinada para el papiloma humano y el sarampion. vector. huesped.
EP2568289A3 (en) Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
AR082281A1 (es) Vectores de parapoxvirus
Shen et al. Development of a subunit vaccine containing recombinant chicken anemia virus VP1 and pigeon IFN-γ
Bhide et al. Cross-protective potential and protection-relevant immune mechanisms of whole inactivated influenza virus vaccines are determined by adjuvants and route of immunization
MX2009012597A (es) Poxvirus de mapache que expresa glicoproteinas de la rabia.
CU20120057A7 (es) Composición vacunal contra el virus del dengue, kit y plásmido
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
EA201500140A1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
Khulape et al. Evaluation of a fusion gene-based DNA prime-protein boost vaccination strategy against Newcastle disease virus
Zhao et al. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice
WO2017116177A3 (ko) 약독화된 돼지열병 바이러스 생마커백신주 및 이를 이용한 경구투여용 백신 조성물
AR085800A1 (es) Vacuna de rinitis equina
EA033242B1 (ru) Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением

Legal Events

Date Code Title Description
FB Suspension of granting procedure